HeartBeam inc (BEAT)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$0.42-1.40%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
QuarterlyIQ Insights · BEAT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-04 · Compared with 1 industry peers
BEAT — officer change
Dated 2026-08-06
CFO — Mr. Eno: Mr. Eno departed the company and entered into a Separation Agreement.
Why it matters: The system has FDA clearance for arrhythmia assessment, but the inputs give no sales or launch figures. Results can show whether the sales push is moving forward.
Supportive ifOn November 12, HeartBeam reports paid sales, customer orders, or a live launch of its cleared 12-lead ECG system.
Worry ifOn November 12, HeartBeam reports no paid sales, orders, or live launch. Or, it says commercialization has slipped.
Why it matters: A signed deal would show that HeartBeam's shift from device sales to licensing is gaining traction. No partner revenue or adoption data is yet provided.
Supportive ifHeartBeam names a partner in a signed license deal. It also reports a launch, sales, or other use of its 3D ECG platform.
Worry ifHeartBeam reports no signed partner deal or partner launch in its next update, or says the licensing plan has stalled.
Why it matters: Heart attack detection would expand the platform beyond arrhythmia checks. The new use is not cleared or available for sale.
Supportive ifHeartBeam reports an FDA filing for heart attack detection. Or, it reports a study that meets its main goal and supports the filing.
Worry ifHeartBeam reports a failed study or a delay to its evidence plan. Or, its next update shows no progress toward an FDA filing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$326 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $989 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,954 loss on $10,000 · 89.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.